GI clinical
trials

Ulcerative
colitis (UC)

Crohn’s
disease (CD)

Irritable Bowel Syndrome
(IBS) pain

Rise up Against
Ulcerative Colitis

ELEVATE UC is a Phase 3 program that includes ELEVATE 52, a 52-week induction and maintenance study, and ELEVATE 12, a 12-week induction study. The ELEVATE UC program is evaluating the efficacy and safety of once-daily, oral etrasimod* in patients with moderately to severely active UC.

• Patients can remain on 5-aminosalicylic acid (5-ASA) and low-dose corticosteroids throughout the trial
• Patients are randomized 2:1 to etrasimod* and placebo
• The treat-through design of the ELEVATE 52 trial does not re-randomize patients at the transition from induction to maintenance
• Patients are eligible to enter an open-label extension and receive investigational drug for up to 5 years

Addressing the Root
of Crohn’s Disease

CULTIVATE is a Phase 2/3 clinical trial program evaluating the efficacy and safety of once-daily, oral etrasimod* in patients with moderately to severely active CD.

• The CULTIVATE clinical trial program is designed as a Phase 2/3 program to facilitate an operationally seamless transition from the Phase 2 portion of the study to the Phase 3 portion
• The operationally seamless design helps ensure continuity for patients, investigators, and study staff, and maintains patient access to investigational study drug throughout the development process

Take a Stand
Against IBS Pain

CAPTIVATE is a Phase 2 clinical program evaluating the efficacy and safety of oral olorinab* in patients experiencing abdominal pain associated with IBS.

• This dose-ranging study includes 1 placebo treatment group and 3 investigational treatment groups; participants have a 75% chance of being randomized to an investigational treatment group
• Patients completing the study have an opportunity to enroll in the long-term extension (LTE) and receive investigational treatment for an additional 52 weeks